Two separate studies spotlight how microbiome-linked mechanisms are increasingly shaping translational R&D in oncology and diagnostics. In one report, researchers summarize evidence that microbial ecology can influence treatment response and complication risk during therapies such as bone marrow transplantation, with sequencing and engineering tools emerging to make the microbiome measurable and potentially actionable. On the translational diagnostics side, bacteriophage-based sensors are positioned as a next-generation approach to detect pathogens with higher specificity, particularly where antimicrobial resistance complicates conventional culture-based workflows and where distinguishing live from dead cells is essential. Together, the work signals that microbiome and phage technologies are converging on deployable measurement tools—an area where biotech developers may be able to differentiate via assay accuracy and clinical utility.